陈茂波当地时间11月26日会继续在英国伦敦的访问，随后转往意大利米兰。 另外，他又提到北部都会区将成为推动创科发展的关键平台，特区政府正加快该区建设，包括放宽规划 限制，采用更具弹性的发展模式，例如片区开发，实现土地绑定产业的融合发展。特区政府也会推出优 惠政策，吸引企业进驻。 而深圳河套地区将成为跨境的创新走廊，推动创新政策，包括资金、人才、货物、数据，以至生物样本 的自由流动，这些都对从事人工智能和生物科技的国际公司具相当吸引力。 陈茂波总结称，香港的发展前景亮丽，欢迎更多英国企业及专业人士来港投资兴业和发展事业，共享庞 大的发展机遇。 智通财经APP获悉，香港财政司司长陈茂波当地时间11月25日抵达英国伦敦并展开访问，与多家来自欧 洲、中东和亚洲的家族办公室的代表会面，向他们介绍香港在金融和创科方面的投资机遇、慈善和影响 力投资的生态，以及优质的生活环境等，欢迎他们来港设立办公室；此外，陈茂波也与一家有意在港来 港设点营运的金融机构会面。 陈茂波之后出席由香港贸发局举办的"香港晚宴"并发表主题演讲，向英国的政商界介绍香港的最新情况 和发展机遇。他强调，"一国两制"继续是香港繁荣稳定的基石，法治和普通法制 ...

Group 1 - Heptagon Pharma announced an update to deepen its global strategic cooperation with AstraZeneca, focusing on discovering and developing next-generation biotherapies, including antibody-drug conjugates (ADC) and T cell engagers (TCE) [1] - AstraZeneca will nominate research projects to Heptagon Pharma annually for the next four years, granting them licensing options for these projects [1] - The partnership reflects the strengthening relationship between Heptagon Pharma and AstraZeneca, showcasing the integration of Chinese biotech companies into the global pharmaceutical ecosystem [1] Group 2 - Prolog Pharma's subsidiary received a drug registration certificate for Cefdinir dry suspension, marking it as the first approved generic antibiotic in China that meets quality and efficacy consistency evaluation [2] - This approval allows the product to participate in national medical insurance negotiations, enhancing its market competitiveness [2] Group 3 - Sinovac's recombinant shingles vaccine has received clinical trial approval from the National Medical Products Administration, targeting individuals aged 40 and above [3] - There are currently two approved shingles vaccines in China, but both have faced poor sales performance, raising concerns about public willingness to vaccinate and the commercialization of high-priced self-funded vaccines [3] Group 4 - AstraZeneca announced a $2 billion investment to expand its manufacturing operations in Maryland, marking its fourth major manufacturing investment in the U.S. this year [4] - The company plans to invest $50 billion by 2030 to enhance its manufacturing and R&D capabilities in the U.S., which is expected to create tens of thousands of jobs [4] Group 5 - Mandi International has submitted its application to the Hong Kong Stock Exchange, focusing on skin health and weight management solutions, with its core brand being the hair loss treatment product Mandi [5] - Mandi has ranked first in the Chinese hair loss medication market for ten consecutive years, with a projected market share of 57% in 2024 [5] - The company faces revenue dependency on a single product, making its IPO progress a point of interest for investors [5]

Group 1 - The Financial Secretary of Hong Kong, Paul Chan, will visit the UK and Italy from November 24 to 28 to promote Hong Kong's advantages and latest developments [1] - In London, Chan will participate in events organized by the Hong Kong Trade Development Council, including a "Hong Kong Dinner" and a luncheon hosted by the Hong Kong General Chamber of Commerce, meeting with local business and financial leaders [1] - During the Milan visit, Chan will lead a delegation of approximately 80 members to attend promotional activities and another "Hong Kong Dinner," including representatives from various government and public institutions [1] Group 2 - The delegation will include members from the Hong Kong Monetary Authority, Invest Hong Kong, and various industry organizations in sectors such as finance, artificial intelligence, information technology, biotechnology, logistics, design, and professional services [1] - Chan will also meet with local business leaders and company executives in Milan to discuss opportunities [1] - The return to Hong Kong is scheduled for November 29, after the conclusion of the visit [1]

- The China Securities Biotechnology Theme Index was launched on August 26, 2015, by China Securities Index Co., Ltd. The index selects listed company securities involved in gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology as index samples to reflect the overall performance of biotechnology listed company securities[3][38] - The index sample space is the same as the China Securities All Index sample space, consisting of A-shares and depository receipts issued by red-chip companies that meet the following conditions: "(1) Non-ST, *ST securities; (2) Other securities: listed for more than one quarter, unless the average daily market value ranks in the top 30 since listing; (3) STAR Market and Beijing Stock Exchange securities: listed for more than one year and two years, respectively"[39] - The index sample selection method includes: (1) Ranking the securities in the sample space by average daily turnover over the past year and removing the bottom 20%; (2) Selecting biotechnology-related companies from the remaining securities as biotechnology theme candidates; (3) Ranking the candidates by average daily market value over the past year and selecting the top 50 securities as index samples[39] - The index's top ten constituent stocks are highly concentrated, focusing on the pharmaceutical industry. As of November 19, 2025, the top ten constituent stocks accounted for 55.26% of the total weight, forming a "CXO + innovative drugs + medical devices" golden triangle combination[40][41] - The index constituent stocks are evenly distributed across different market value ranges, with weights of 35.79% for stocks with a market value of over 100 billion, 44.24% for stocks with a market value between 200-1000 billion, and the rest distributed among other ranges[42][43] - The index constituent stocks are mainly concentrated in the biological medicine III, medical services, chemical preparations, and medical devices industries, with weights of 42.33%, 20.99%, 17.33%, and 11.97%, respectively[44][46] - The index constituent stocks have high exposure to concepts such as industry leaders, comprehensive private enterprises, main trading forces, dual circulation, fund heavy positions, and innovative drugs, with exposure rates of 70.56%, 64.78%, 64.58%, 62.60%, 62.48%, and 62.16%, respectively[47][48] - The index's current style is characterized by small market value, high liquidity, and high momentum. As of October 31, 2025, the index's market value style is significantly negatively exposed compared to the China Securities 800 Index, with higher liquidity and trading activity[48][51][52] - The index's PE valuation is near the historical average, and the PB valuation is near the historical -1 standard deviation, indicating a high safety margin and potential for upward valuation[53][54] - The index's profitability is outstanding, with expected revenue growth rates of 6.54%, 6.00%, and 13.76% for 2025, 2026, and 2027, respectively, and expected net profit growth rates of 52.09%, 18.58%, and 24.11% for the same years[55][56][57][58]

Group 1 - The core viewpoint is that while new industries like artificial intelligence and biotechnology have potential, the focus should be on companies' ability to achieve profitability and survival certainty, which is more challenging in new sectors compared to traditional industries [1] - Traditional industries have been sluggish in recent years, but leading companies with scale, capital, and management advantages are still able to sustain themselves, which is reflected in their stock prices [1] - Many quality companies in traditional industries are currently valued reasonably or even low, making it a good time to invest in large companies and major indices like the CSI 300 and A50, which are essential for supporting the Chinese economy [1] Group 2 - The Shanghai Composite Index closed at 3834.89, down 96.16 points or 2.45%, while the Shenzhen Component Index fell by 442.75 points or 3.41% to 12538.07 [2] - The CSI 300 Index decreased by 111.34 points or 2.44%, closing at 4453.61, indicating a broader market decline [2] - The sector performance shows that cultural media had a slight increase of 0.10%, while agriculture and household appliances saw declines of 0.65% and 0.74% respectively [3]

1.谈"热门"赛道：迟早要面对惨烈竞争 人工智能、生物科技、新能源等领域，随着时间推移，迟早也会走到产能扩张、竞争加剧的那一步，这 是市场规律，只是早晚的问题。 新行业，我承认它们的方向肯定没问题，未来也会产生机会。但从投资角度，我更关注这些企业能否真 正跑出确定性的盈利和生存能力。 它们大多是高投入的行业，烧钱快，周期长，一旦风向发生变化，或者长期不盈利，投资者的信心就会 被彻底打散。这种行业更多靠钱堆，而不是靠确定性的利润支撑。 你去翻那些代表"创新"的指数基金，里面的企业未来十年真正能活下来的，有多少？我心里是有数的。 2.谈"老赛道"：估值已在难得的位置 （原标题：林园重磅发声：当下，我只敢买这两类"保命"资产） 11月20日下午，百亿私募大佬林园公开发声，他直言：在全市场追逐科技热点的当下，他投资最底层的 核心是生存与盈利。 以下是林园最新观点的精华浓缩： 我们未来主要找两类企业：能让人快乐的和能让人活得更长的。 老祖宗说得好，人活一世，吃喝二字。吃喝是永恒需求。与此同时，人还希望活得更长、活得更好。 食品、消费这些行业的供需调整的更快，市场纠错能力更强。它们不需要巨额投入来维持增长；一旦产 能过多 ...

Group 1 - The core argument emphasizes that emerging industries like AI, biotechnology, and renewable energy will eventually face increased competition and capacity expansion, which is a natural market progression [3][10] - The company acknowledges the potential of new industries but stresses the importance of profitability and survival capability from an investment perspective, indicating a preference for traditional industries [3][13] - Traditional industries have experienced a downturn, but leading companies have maintained their positions due to scale, capital, and management advantages, which are reflected in their stock prices [4][16] Group 2 - The company believes that core indices like the CSI 300 and A50 are currently undervalued and can support the fundamentals of the Chinese economy, presenting a good investment opportunity [3][17] - The focus remains on consumer-related sectors, particularly those linked to the "mouth economy," which are characterized by quicker market corrections compared to fixed asset investments [3][19] - The company maintains that industries related to food and health will continue to have persistent demand, making them attractive for investment [3][22][44] Group 3 - The company expresses caution regarding the high uncertainty in new industries, which often require significant investment and have longer cycles to profitability [4][14] - The investment strategy prioritizes companies that can provide consistent profits and have a sustainable business model, rather than those that rely on speculative growth [4][51] - The company highlights the importance of understanding the long-term viability of investments, particularly in traditional sectors that have proven resilient over time [4][56]

其次是AI泡沫论。这个咱们在前面文章也讲过了，科技巨头投入了数万亿美元建设数据中心和AI能力，可何时能真正看到这些投入 带来的回报？英伟达则是那个关键，不夸张地说全球AI个股的表现都会受英伟达影响，甚至于美股的涨跌也要系英伟达于一身。不 过英伟达财报还是很给力的，无论是营收、利润还是对下一季度的展望，均显著高于市场预期，盘后股价也受影响大涨。今天日韩 股市能暴涨两三个点，也是因为深度绑定了英伟达产业链。不过财报虽然超出了华尔街预期，但不及陆家嘴预期，国内相关产业链 个股全都高开低走。虽然有不少分歧，但是美股看起来短期仍有支撑的逻辑。 来源：财经林妹妹 美股，日股，黄金，虚拟货币，大宗品过去的一周几乎全军覆没，A股走势也一言难尽，看起来又要触碰3900了。咱们今天主要来 分析一下原因，再说说对未来市场的判断。 | | | A股重要指数 | | | | --- | --- | --- | --- | --- | | 名称 | 最新 | 涨跌 | 涨幅 | 年初至今 | | 上证指数 | 3931.05 | -15.69 | -0.40% | +17.28% | | 深证成指 | 12980.82 | -99.27 ...

Market Overview - The Hong Kong stock market showed signs of recovery with the Hang Seng Index rising by 0.02%, while the Hang Seng China Enterprises Index fell by 0.08% and the Hang Seng Tech Index dropped by 0.58%, marking five consecutive days of decline [1] - Market sentiment remains low, but there are indications of a potential rebound [1] Sector Performance - Major technology stocks such as Baidu, Meituan, and Kuaishou saw gains, with Baidu up by 2.43% and Kuaishou up by 2.28%, while Xiaomi continued to decline, dropping nearly 3% to a new low [3][5] - Financial stocks, including banks and insurance companies, performed actively, with several Chinese brokerage stocks showing gains despite a high open and subsequent decline [3][9] - The real estate sector remained strong in the afternoon, with Sunac China and Zhongliang Holdings leading the gains [3][8] - The biopharmaceutical, home appliance, and aviation sectors also showed relative activity [3] Real Estate Market Insights - According to Centaline Property, Hong Kong's residential market recorded over 1,700 transactions in October, marking the ninth consecutive month of over 1,000 transactions, matching the longest record from March to November 2019 [7] - The month also saw at least 64 transactions exceeding HKD 50 million, totaling over HKD 6.8 billion, a new high for the year [7] - Major international banks, including Morgan Stanley and Citigroup, predict a recovery in the Hong Kong real estate market post-2025 [7] Brokerage Sector Developments - Chinese brokerage stocks saw significant increases, with Financial Street Securities rising over 4% [9][10] - The announcement of major asset restructuring plans by several brokerages is expected to enhance industry consolidation and competitiveness [9] Semiconductor Sector Activity - The semiconductor sector was active, with stocks like Contrelon rising over 8% [10][12] - Reports indicate that the U.S. may delay the imposition of long-promised semiconductor tariffs, which could impact the sector positively [11] New Energy Material Sector Decline - The new energy materials sector faced declines, with companies like China Silicon Corporation dropping over 16% [13] - The lithium battery sector also saw significant drops, with CATL falling by 5.66% [14][15] Coal Sector Insights - Coal prices have risen above RMB 830 per ton, but short-term price increases may be stabilizing [16] - The coal industry's supply-demand dynamics have fundamentally shifted since May, indicating a long-term upward trend in coal prices [16] Individual Stock Highlights - Gakos-B surged by 19.97% following the approval of its self-developed KRAS G12C inhibitor for commercialization [18] - Southbound capital saw a net inflow of HKD 15.992 billion, indicating strong investor interest [21] Future Market Outlook - CITIC Securities anticipates that the Hong Kong stock market will benefit from internal and external economic policies, predicting a second round of valuation recovery and performance resurgence by 2026 [23] - Suggested investment directions include technology sectors, healthcare, resource commodities, essential consumer goods, and sectors benefiting from RMB appreciation [23]

Group 1 - The Hang Seng Tech Index has decreased by 0.82% as of November 20, 2025, with mixed performance among constituent stocks, where Baidu Group-SW led with a rise of 2.79% and Kingsoft fell by 8.98% [1] - Kuaishou Technology reported a 14.2% year-on-year revenue growth in Q3, reaching 35.6 billion yuan, with operating profit increasing by 69.9% to 5.3 billion yuan [1] - The Hang Seng Tech Index ETF has seen a 4.59% increase over the past three months, with a current trading price of 0.8 yuan [1] Group 2 - CITIC Securities predicts a rebound in the Hong Kong stock market in 2026, driven by a recovery in fundamentals and significant valuation discounts [2] - The report suggests five long-term investment directions, including the technology sector, healthcare, resource commodities, essential consumer goods, and sectors benefiting from RMB appreciation [2] Group 3 - The latest size of the Hang Seng Tech Index ETF is 4.278 billion yuan [3] - The ETF has reached a new high with 5.639 billion shares outstanding, and has seen continuous net inflows over the past 15 days totaling 69.6169 million yuan [4] - The top ten weighted stocks in the Hang Seng Tech Index account for 68.89% of the index, including Alibaba-W, SMIC, and Tencent Holdings [4]